<DOC>
	<DOC>NCT01706510</DOC>
	<brief_summary>Assess the pharmacodynamic effect of ticagrelor vs. Clopidogrel in American Indian patients with stable coronary artery disease.</brief_summary>
	<brief_title>Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients</brief_title>
	<detailed_description>A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
	<mesh_term>Purinergic P2 Receptor Antagonists</mesh_term>
	<criteria>Documented stable CAD fulfilling any of the following, and taking 81mg ASA daily treatment: Females must be post menopausal for at least one year or surgically sterile for at least 6 months and negative urine pregnancy test Selfidentified as American Indian Genetic must sign the informed consent for genetic and biological sample banking. Any indication for oral anticoagulant or dual antiplatelet treatment Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers within 14 days and during study treatment and during: Increased bleeding risk including: Diabetic patients with HbAlC &gt; 10% at screening Contraindication to clopidogrel, ASA, or ticagrelor A history of alcohol and/or substance abuse that could interfere with conduct of the trial Patients requiring dialysis Patients scheduled for revascularization (e.g., PCI, CABG) during the study period Any acute or chronic unstable condition in the past 30 days Known active or recurrent hepatic disorder Patients who had ACS or stent placed within 12 months of screening History of Uric Acid nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Clopidogrel</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Purinergic P2Y Receptor Antagonists</keyword>
	<keyword>Purinergic P2 Receptor Antagonists</keyword>
	<keyword>Purinergic Antagonists</keyword>
	<keyword>Purinergic Agents</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
</DOC>